Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics: Difference between revisions
No edit summary |
No edit summary |
||
| Line 13: | Line 13: | ||
===Prevalence=== | ===Prevalence=== | ||
*The | * G6PD deficiency is affecting 400 million people worldwide. <ref name="pmid17611006">{{cite journal |vauthors=Mason PJ, Bautista JM, Gilsanz F |title=G6PD deficiency: the genotype-phenotype association |journal=Blood Rev. |volume=21 |issue=5 |pages=267–83 |date=September 2007 |pmid=17611006 |doi=10.1016/j.blre.2007.05.002 |url=}}</ref> | ||
*The prevalence of Gucose-6-phosphate dehydrogenase is approximately per 100,000 individuals worldwide. | |||
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide. | *In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide. | ||
*The prevalence of [disease/malignancy] is estimated to be [number] cases annually. | *The prevalence of [disease/malignancy] is estimated to be [number] cases annually. | ||
Revision as of 17:07, 30 July 2018
|
Glucose-6-phosphate dehydrogenase deficiency Microchapters |
|
Differentiating Glucose-6-phosphate dehydrogenase deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics |
|
FDA on Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics |
|
CDC on Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics |
|
Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics in the news |
|
Blogs on Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics |
|
Directions to Hospitals Treating Glucose-6-phosphate dehydrogenase deficiency |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahda Alihashemi M.D. [2]
Overview
Epidemiology and Demographics
Incidence
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
- In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
Prevalence
- G6PD deficiency is affecting 400 million people worldwide. [1]
- The prevalence of Gucose-6-phosphate dehydrogenase is approximately per 100,000 individuals worldwide.
- In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
- The prevalence of [disease/malignancy] is estimated to be [number] cases annually.
Case-fatality rate/Mortality rate
- In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
- The case-fatality rate/mortality rate of [disease name] is approximately [number range].
Age
- Patients of all age groups may develop [disease name].
- The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
- [Disease name] commonly affects individuals younger than/older than [number of years] years of age.
- [Chronic disease name] is usually first diagnosed among [age group].
- [Acute disease name] commonly affects [age group].
Race
- There is no racial predilection to [disease name].
- [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
Gender
- [Disease name] affects men and women equally.
- [Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
Region
- The majority of [disease name] cases are reported in [geographical region].
- [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
Developed Countries
Developing Countries
References
- ↑ Mason PJ, Bautista JM, Gilsanz F (September 2007). "G6PD deficiency: the genotype-phenotype association". Blood Rev. 21 (5): 267–83. doi:10.1016/j.blre.2007.05.002. PMID 17611006.
|
Glucose-6-phosphate dehydrogenase deficiency Microchapters |
|
Differentiating Glucose-6-phosphate dehydrogenase deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics |
|
FDA on Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics |
|
CDC on Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics |
|
Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics in the news |
|
Blogs on Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics |
|
Directions to Hospitals Treating Glucose-6-phosphate dehydrogenase deficiency |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.D. [4]
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Epidemiology and Demographics
- G6PDD is said to be the most common enzyme deficiency disease in the world, affecting approximately 400,000,000 people globally.[1]
- A side effect of this disease is that it confers protection against malaria, in particular the form of malaria caused by Plasmodium falciparum, the most deadly form of malaria.
- A similar relationship exists between malaria and sickle-cell disease. An explanation is that cells infected with the Plasmodium parasite are cleared more rapidly by the spleen. This phenomenon might give G6PD deficiency carriers an evolutionary advantage.